At AMP 2022, Dr. Peter Soukas presented the largest set of real-world data on Shockwave IVL in CLI patients. These data include results from patient groups historically not included in other PAD studies, such as Rutherford 6 and dialysis patients, and patients with single or absent vessel run-off. These data show the significant reduction of stenosis post-IVL in these patients, the minimal complications and the consistent results across multiple vessel beds. In this presentation Dr. Soukas shares why these data are important for physicians who treat CLI, and how his calcium modification algorithm has changed over time with IVL.
Read More
Topics:
Peripheral IVL,
Peripheral Conferences,
Peripheral Clinical Data,
Shockwave M5 & Shockwave M5+
Calcified lesions in CLTI patients pose a number of hurdles for endovascular therapy including acute and sub-acute recoil, flow-limiting dissections and distal embolization. In this presentation from Charing Cross 2022 Dr. Thulasidasan shares how Shockwave IVL has improved his treatment for CLTI patients with low complications and increased durability. Dr. Thulasidasan walks through case examples with IVL in CLTI patients and states how the data supporting IVL backs up what he’s seeing in practice.
Read More
Topics:
Peripheral IVL,
Peripheral Conferences,
Peripheral Clinical Data
We had an amazing time seeing you all in person at conferences this past quarter. We accomplished a great deal these past three months—from sharing the randomized Disrupt PAD III Study results at SCAI 2022 to launching Shockwave M5+ across the globe. JSCAI also published two articles discussing peripheral IVL for treatment of calcified common femoral artery disease, and the mid-term outcomes from the randomized Disrupt PAD III Trial. Check out the latest in the PulsePoint newsletter!
Read More
Topics:
Coronary IVL,
Peripheral IVL,
IVL Technology,
PulsePoint Newsletter
In this three-episode tutorial series, Dr Stefano Fazzini and Dr Michel Bosiers provide an excellent overview on how IVL removes the barriers of calcified hostile access and expands treatment boundaries in EVAR and TEVAR procedures by changing vessel compliance, facilitating luminal gain and significantly reducing complications.
Read More
Topics:
Peripheral IVL,
Peripheral Clinical Data
This year has been “chalk” full of good vibrations at Shockwave! We launched our most efficient IVL catheter yet, the faster-pulsing Shockwave M5+, and its effects have been helping patients with calcified PAD across the globe ever since. Our data also got deeper, with the Disrupt CAD III one-year data published in JSCAI, demonstrating Coronary IVL’s excellent safety and effectiveness outcomes at 30 days out to one year. We heard from physicians like Dr. B. Clay Sizemore on using Coronary IVL in a no-surgical-backup hospital, and Dr. Alexandra Lansky regarding gender disparities in cardiovascular disease. To top it all off, Fast Company recognized Shockwave as one of the World’s Most Innovative Companies for 2022. Check out all of this and more in the latest PulsePoint Newsletter!
Read More
Topics:
Coronary IVL,
Peripheral IVL,
IVL Technology,
PulsePoint Newsletter
It’s no exaggeration that calcium represents the Achilles heel of endovascular treatment. As the patient population continues to evolve in complexity we need solutions that can treat severe calcified disease in an efficacious, safe and durable way. Listen as Dr Konstantinos Stavroulakis shares the outcomes of his recent publication of Intravascular Lithotripsy (IVL) and DCB in severely calcified femoropopliteal lesions followed out to 12 months and understand why he believes IVL is a game changer in the treatment of complex real world patients.
Read More
Topics:
Peripheral IVL,
Peripheral Clinical Data
In a few weeks, we are headed to a city known for its sunshine and southern hospitality, Atlanta, Georgia, where SCAI 2022 is taking place this year. At the conference, leading calcium experts will share the 1-year results from the Randomized Disrupt PAD III Trial and 1-year sex specific outcomes with Coronary IVL.
Read More
Topics:
Coronary IVL,
Peripheral IVL,
IVL Technology,
Peripheral Conferences,
SWAV News,
Shockwave C2,
Coronary Conferences,
Shockwave S4,
Shockwave M5 & Shockwave M5+
The presence of calcium can pose significant challenges in achieving optimal procedural outcomes in PAD treatment and can pose as a barrier to the delivery of large bore access devices. Shockwave IVL is shifting the paradigm in the way physicians approach calcium by simplifying procedures in an efficacious and safe manner. Now the next generation of peripheral IVL technology is here: Shockwave M5+! The Shockwave M5+ extends treatment options with the introduction of its new features; faster pulsing, an extended working length and expanded size matrix.
Read More
Topics:
Peripheral IVL,
Peripheral Clinical Data,
Shockwave M5 & Shockwave M5+
Based on Shockwave’s recognition on Fast Company’s 2022 list of the World’s Most Innovative Companies in the medical device sector for “bringing good vibrations to heart procedures,” we sat down with Shockwave CEO Doug Godshall for a Q&A to discuss how innovation is fostered at SWAV and why continual innovation is imperative to the future success of the company.
You can also read more about the honor in the company’s press release, in which Doug is quoted saying, “Shockwave Medical was founded with innovation at our core…not only for pioneering revolutionary and proprietary IVL technology, but also for the ways that innovation permeates every aspect of our business. We are continually evolving and transforming how we do things as we seek to astound our customers with life changing products for the treatment of calcified cardiovascular disease.”
Read More
Topics:
Coronary IVL,
Peripheral IVL,
IVL Technology,
SWAV News,
ChalkTalk Podcast
2021 was Shockwave’s best year yet! Although it brought challenges, with it came immense opportunities which allowed us to grow and exceed expectations. As we push on into 2022, we are excited for what the year will bring but most importantly, for the opportunities to continue to help improve patient outcomes across the globe. But before we get started, let’s review the highlights of last quarter. We released four data releases, including our 1-year results of our Coronary IVL pivotal study at TCT this year, making it a monumental event. We had some exciting peer-reviewed publications come out, enrolled the first patient in the Disrupt BTK II Study, and much more. Read the latest PulsePoint for all the updates!
Read More
Topics:
Coronary IVL,
Peripheral IVL,
IVL Technology,
PulsePoint Newsletter
